Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Summary

This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.

Timeline

Start

2012-07

Primary completion

2013-07

Completion

2014-01

Outcome

Missed primary endpoint

paper In the KB003 treated group, FEV1 at week 24 improved to 118 mL compared with 54 mL in the placebo group (p=0.224). PMID 26739717 ↗

Publications

• Molfino NA, Kuna P, Leff JA, Oh CK, Singh D, Chernow M, Sutton B, Yarranton G. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open. 2016 Jan 6;6(1):e007709. doi: 10.1136/bmjopen-2015-007709.

Drugs

Indications